CITC LTD and partners on personalized stem cell therapies for injury and diseases of the CNS

CITC Ltd has recently concluded a non-esclusive license agreement with Provendis GmbH, a technology transfer agency of 27 universities of North Rhine-Westphalia, including the University of Bonn, for a manufacturing technology of autologous induced neural stem cells (iNSC) from adult cells that are harvested from simple skin biopsy or from other somatic sources.

Directly reprogrammed autologous iNSCs are seen as a powerful and safe tool to treat patients with neurological illnesses and injuries, that may occur while they age.

In line with CITC ltd’s governing mission, this license agreement helps develop further our unique portfolio of technologies and Intellectual Property in the field of molecular diagnostics, nano-medicine, and advanced therapies, and to establish a translational path toward clinical use in humans, subject to successful clinical trials.

See the Full Article HERE

This entry was posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research. Bookmark the permalink.